ReviewSeminars in liver disease2017
Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance.
Review in Seminars in liver disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS).International journal of surgery (London, England) · 2026Guideline
- Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Guideline
- Guideline
- Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.Gut · 2021Pooled it
- Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium.Hepatology (Baltimore, Md.) · 2026Review
- Immunosenescence and cancer predisposition in pediatric transplant recipients: An emerging paradigm.World journal of transplantation · 2026Review
- Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances.Cancers · 2024Review
- Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis.Journal of the National Cancer Center · 2023Article
- Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis.Cancer research communications · 2023Article
- Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Early detection of hepatocellular carcinoma: roadmap for improvement.Expert review of anticancer therapy · 2022Article
- Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?Hepatology (Baltimore, Md.) · 2022Review
- A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma.Cancer cell international · 2021Article
- Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.Hepatology (Baltimore, Md.) · 2020Article
- The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid.Ultrasonography (Seoul, Korea) · 2020Article
- Epidemiology and surveillance for hepatocellular carcinoma: New trends.Journal of hepatology · 2020Review
- Harms of hepatocellular carcinoma surveillance.Current hepatology reports · 2019Article
- Surveillance of hepatocellular carcinoma by medical imaging.Quantitative imaging in medicine and surgery · 2019Article
- A global view of hepatocellular carcinoma: trends, risk, prevention and management.Nature reviews. Gastroenterology & hepatology · 2019Review
- Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?Clinical and molecular hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Overdiagnosis, the detection of clinically insignificant disease that would not otherwise impact the patient's lifespan, is a phenomenon that has been described in several solid tumors, such as prostate, breast, thyroid, and lung cancers. Population-based efforts to reduce hepatocellular carcinoma (HCC) mortality in cirrhosis patients by screening and early detection may result in the overdiagnosis of HCC. One of the harms of overdiagnosis is subsequent overtreatment, which can result in increased costs, as well as physical side effects, psychological harms, and poorer quality of life. In this review, the authors explore the potential for overdiagnosis in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.